Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peptide Alarm Therapy (PAT) + PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
NCT05338658Phase 1Recruiting
- Sponsor
- Masonic Cancer Center
- Start
- May 2023
- Primary completion
- Jan 2027
- Modality
- Prophylactic Vaccines, Peptides, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Peptide Alarm Therapy in solid tumor, sponsored by Masonic Cancer Center. Primary endpoint: Maximum Tolerated Dose at Day 43. Started May 2023; status: recruiting.
02
Drugs
Peptide Alarm Therapy
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05338658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05338658.